Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0062

Congress meeting · Dr. Hiroshi Zimmermann

21 Mar 2026 · In person · Dr. Hiroshi Zimmermann, Gustave Roussy · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0062—

Capture insight from this engagement

Location: Gustave Roussy
Therapeutic area: Oncology
Country: France
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround

Scientific content used

PD-L1 testing pathway infographic
irAE management guide

Questions raised

How should grade 2 infusion reactions be managed without steroids?
What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Congress meeting with radiation oncologist at Gustave Roussy. Discussed pd-l1 testing turnaround.

Insights captured (1)

Capture insight

INS-0024Medium
PD-L1 testing turnaround
PD-L1 testing turnaround: gap in current materials reported by radiation oncologist (FR).
Deduplicated

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 5
Depth of exchange: 3
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0062

Audit history (0)

All create, update and approval events for this record

No audit events in sample data